The Research & Development Committee
The Research & Development Committee consists of up to five
members elected by the Board
of Directors from among its members. One member is designated as
chair and one member is an employee representative.
The Research & Development Committee was established in March
2017 in light of the updated research and development strategy and
priorities as a temporary board committee. In 2018, the Board decided
that the Research & Development Committee should continue as a
permanent committee and revised the charter to include additional
The Board of Directors has in March 2019 elected the following
members to the Research & Development Committee:
Mackay (re-elected, member and chair since 2018;
Daniels (re-elected, member since the establishment in 2017;
Gregoire (re-elected, member since the establishment in 2017;
Rantzau (re-elected, member since 2018; employee representative;
Roles and responsibilities
The Research & Development Committee assists the Board with
oversight of the research and development strategy, the pipeline, the
R&D organisation, and other tasks on an ad hoc basis as
specifically decided by the Board.
The Research & Development Committee consists of three members
who are independent, including the chair, as defined in the Danish
Corporate Governance Recommendations and one member, the employee
representative, who is non-independent. According to the Danish
Corporate Governance Recommendations a majority of the members of a
board committee shall qualify as independent. Hence, the composition
of the Research & Development Committee adheres to the Danish
Corporate Governance Recommendations.
The Research & Development Committee conducted five meetings in
2018. All Research & Development Committee members attended all
committee meetings within the member’s term in 2018. Please refer to
the Annual Report on pp. 50-51 for a detailed attendance overview.
Research & Development Committee Report 2018
The R&D Committee was established in March 2017 as a temporary
committee. In 2018 the Board of Directors decided that the R&D
Committee should be a permanent committee. The R&D Committee works
according to an Annual Work Plan with fixed agenda items. In addition,
the R&D Committee meets when developments require additional
meetings. The R&D Committee has in 2018 met five times and dealt
with the following matters:
R&D pipeline update
- Regularly reviewed progress of the development project
pipeline, including initiation and results of clinical trials,
submission of application for marketing authorisations, and receipt
of marketing authorisations for key development projects.
- Reviewed progress of the research project pipeline, including
key challenges and initiatives within early innovation and new
Progress within external innovation sourcing
- Discussed the increased need for external innovation
- Regularly reviewed potential as well as completed
external innovation sourcing opportunities, including potential
acquisitions and licensing opportunities.
Implementation of the revised R&D Strategy
- Reviewed the overall strategic objectives for the next 3-5
- Reviewed the research strategy within oral glp-1,
Biopharm, NASH and atherosclerosis.
- Reviewed R&D
governance, including restructurings and key priority initiatives
- Reviewed the future organisational R&D
R&D Committee matters and governance
- Reviewed and endorsed the Annual Work Plan for 2019.
- Reviewed and suggested changes to the R&D Committee
- Conducted private meetings without the assigned
executive being present.
- Reviewed and endorsed a report on
the R&D Committee’s activities in 2018.
Special focus areas
- GLP-1 (subcutaneous and oral): Reviewed results of clinical
trials conducted and discussed potential additional research and
development activities to further explore opportunities within GLP-1
of as well as competitor initiatives.
- NASH and
atherosclerosis: Discussed the potential opportunities to address
- External innovation sourcing: Reviewed
potential external research collaborations as well as
- R&D organisation: Discussed elements to
further enhance the R&D organisations’ performance,
re-allocation of resources and succession management.ses: Discussed
the intensified exploration of current assets in adjacent disease
areas of high unmet need as well as the identification of new assets
using the company’s existing technology platform.